| 22056 |
Buprenorphine |
Buvidal® |
Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. |
Rapid Review complete |
5th June 2024 |
 |
| - |
Buprenorphine/Naloxone |
Suboxone® |
Management of opiate addiction |
NCPE Assessment Process Complete |
22nd May 2014 |
|
| - |
Burosumab |
Crysvita® |
Treatment of X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children 1 year of age and older and adolescents with growing skeletons. |
NCPE Assessment Process Complete |
12th March 2020 |
|
| 23005 |
Burosumab |
Crysvita® |
Burosumab (Crysvita®) is indicated for X-linked hypophosphataemia in adult patients. |
NCPE Assessment Process Complete |
1st August 2024 |
|
